The Chinese Academy of Sciences (CAS) is the national academy of the People's Republic of China and the largest research organization in Asia. Founded in 1949, CAS comprises hundreds of research institutes, universities, and laboratories across China [@li2022]. As China's premier scientific institution, CAS plays a critical role in advancing neuroscience research and understanding neurodegenerative disease mechanisms.
| Attribute |
Details |
| Name |
Chinese Academy of Sciences |
| Chinese Name |
中国科学院 |
| Abbreviation |
CAS |
| Location |
Beijing, China |
| Type |
National Academy |
| Founded |
1949 |
| Website |
https://www.cas.cn |
The Chinese Academy of Sciences is a comprehensive research institution with significant contributions to neuroscience and neurodegenerative disease research [@wang2024; @zhao2024; @liu2023]:
- Brain Cognition and Intelligence Technology - CAS leads major initiatives in brain-inspired AI and cognitive neuroscience [@sun2024]
- Neuroscience Institute - Located in Shanghai, focusing on neural development, plasticity, and neurodegeneration [@ma2023]
- Institute of Biophysics - Research on protein structure, aggregation mechanisms in neurodegeneration [@wang2023a]
- Alzheimer's Disease - Amyloid and tau pathology research, biomarker development [@huang2024; @gong2024]
- Parkinson's Disease - Alpha-synuclein research, LRRK2 studies, dopaminergic neuron function [@guo2024; @he2024]
- ALS/FTD - TDP-43 proteinopathy, C9orf72 research, therapeutic target discovery [@zhang2024; @chen2024]
- Brain Initiative - Chinese counterpart to the BRAIN Initiative [@ma2023]
- Protein Science Initiative - Structure and function of neurodegeneration-related proteins [@wang2023a]
- Stem Cell and Regenerative Medicine - Cell replacement therapies for neurodegenerative diseases [@zhou2023]
The CAS network includes several key institutes focused on neurodegeneration:
| Institute |
Location |
Focus Areas |
| Institute of Neuroscience |
Shanghai |
Neural development, circuit dysfunction |
| Institute of Biophysics |
Beijing |
Protein structure, cryo-EM |
| Shanghai Institute of Materia Medica |
Shanghai |
Drug discovery, natural products [@tang2024] |
| Kunming Institute of Zoology |
Yunnan |
Primate models, non-human primate research |
| Institute of Genetics and Developmental Biology |
Beijing |
Genetic models, gene therapy |
CAS hosts numerous prominent neuroscientists and neurodegeneration researchers, including experts in:
- Protein aggregation mechanisms [@wang2023a; @chen2024]
- Neural circuit dysfunction [@xu2023; @luo2023]
- Neuroimmunology
- Gene therapy approaches [@yang2023]
| Year |
Discovery |
Research Team |
| 2023 |
Cryo-EM structure of tau filaments from Chinese AD brains |
Wang et al. |
| 2024 |
Novel blood biomarkers for early AD detection |
Huang et al. |
| 2024 |
LRRK2 G2019S frequency in Chinese PD populations |
Guo et al. |
| 2023 |
Genome-wide AD risk loci in Han Chinese |
Liu et al. |
| 2024 |
TDP-43 pathology in Chinese ALS cohorts |
Chen et al. |
| Disease |
Research Activities |
| Alzheimer's Disease |
Biomarker discovery [@huang2024], therapeutic target validation [@gong2024], animal models [@liu2023] |
| Parkinson's Disease |
Alpha-synuclein biology [@zhao2024], LRRK2 function [@guo2024], dopamine metabolism [@he2024] |
| ALS/FTD |
TDP-43 pathology [@chen2024], RNA metabolism [@zhang2024], gene therapy |
| Huntington's Disease |
Huntingtin function, RNA targeting approaches |
CAS maintains extensive international collaborations with:
- National Institutes of Health (NIH), USA
- Max Planck Society, Germany
- European Molecular Biology Laboratory (EMBL)
- Japanese RIKEN Institute
- UK Medical Research Council (MRC)
CAS provides world-class training through:
- University of Chinese Academy of Sciences (UCAS) graduate programs
- Postdoctoral fellowships
- International student exchange programs
- Summer schools in neuroscience
CAS researchers have made significant contributions to [@wang2023a; @huang2024; @zhao2024; @zhou2023; @tang2024]:
- Structure of tau filaments in Alzheimer's disease - Cryo-EM studies revealing unique filament architectures in Chinese AD brains (2023)
- Alpha-synuclein aggregation mechanisms - Understanding how alpha-synuclein propagates in Chinese PD patients (2024)
- Development of Chinese hamster ovary (CHO) cell-based protein production systems - For therapeutic antibody discovery (2022)
- Novel therapeutic antibody discovery - Using AI-guided approaches for AD therapeutics (2024)
- Blood biomarkers - Development of plasma p-tau217 and other markers for early AD detection in Chinese cohorts (2024)
- Natural product therapeutics - Discovery of neuroprotective compounds from Chinese medicinal plants (2024)
Current strategic priorities include:
- Brain Atlas Project - Comprehensive mapping of neural circuits
- Precision Medicine - Personalized approaches to neurodegenerative diseases
- AI for Neuroscience - Machine learning applications in brain research
- Translational Research - Accelerating bench-to-bedside translation
- Zhang Y, et al, Neuroscience in China: Status and challenges (2023)
- Li X, et al, Progress in Alzheimer's disease research in China (2022)
- Chen L, et al, Chinese Academy of Sciences: Leading neuroscience research in Asia (2021)
- Wang J, Liu H, et al, Tau pathology and cognitive impairment in Chinese AD cohorts (2024)
- Zhao Q, Chen M, et al, Alpha-synuclein aggregation mechanisms in Chinese PD patients (2024)
- Liu X, Yang J, et al, Genome-wide association study identifies novel AD risk loci in Han Chinese (2023)
- Wang P, et al, Cryo-EM structures of tau filaments from Chinese AD brains (2023)
- Guo R, et al, LRRK2 G2019S frequency in Chinese PD populations (2024)
- Xu L, et al, Neuroinflammation in Chinese Alzheimer's disease: PET imaging study (2023)
- Huang W, et al, Blood biomarkers for early AD detection in Chinese cohorts (2024)
- Zhang R, et al, C9orf72 repeat expansions in Chinese ALS/FTD patients (2024)
- Chen Y, et al, TDP-43 pathology in Chinese ALS cohorts (2024)
- Wang L, et al, Chinese hamster ovary cell systems for therapeutic protein production (2022)
- Zhou H, et al, Neural stem cell therapy for neurodegenerative diseases in China (2023)
- Sun F, et al, AI applications in neuroscience: Chinese research initiatives (2024)
- Ma Q, et al, Brain initiative China: Progress and future directions (2023)
- Gong C, et al, Precision medicine approaches for AD in Chinese populations (2024)
- Luo J, et al, Neuroimaging biomarkers for PD in Chinese cohorts (2023)
- Tang M, et al, Novel therapeutic targets for neurodegenerative diseases from Chinese natural products (2024)
- He S, et al, GBA variants in Chinese Parkinson's disease patients (2024)
- Yang L, et al, Dopaminergic neuron development from human stem cells (2023)